Clinical Trial Update: REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT [Phase 3]

View source ↗

Summary

Phase 3 trial REDECT 2 for detecting clear cell renal cell carcinoma with PET/CT has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Cancer
• Renal Cell Carcinoma

Snippet

Sponsor: Heidelberg Pharma AG | Conditions: Renal Cell Carcinoma, Kidney Cancer | Phase 3 | Status: WITHDRAWN